

44. The method according to Claim 43, wherein said condition is characterized by the occurrence of seizures.

45. The method according to Claim 43, wherein said condition is epilepsy.

Sub  
Dis  
46. The method according to Claim 43, wherein said method results in a decrease in seizure proneness.

47. The method according to Claim 43, wherein said host is a mammalian host.

C/ ant  
48. A method of treating a host suffering from a condition resulting from excessive activity of glutamate receptors, said method comprising:  
administering to said host an amount of a serine protease inhibitor effective to treat said host for said condition.

49. The method according to Claim 48, wherein said excessive activity results from hypoxia, head trauma or stroke.

50. The method according to Claim 48, wherein said host is a mammalian host.

Sub  
Dis  
51. A method of preventing the onset of a condition characterized by increased synaptic responsiveness in a host, which method comprises:  
administering to said host an amount of a serine protease inhibitor effective to prevent onset of said condition.

52. The method according to Claim 51, wherein said condition is characterized by the occurrence of seizures.

53. The method according to Claim 51, wherein said condition is epilepsy.

Sub  
Dis  
54. The method according to Claim 51, wherein said host is a mammalian host. --